Skip to main content
Top
Published in: World Journal of Surgical Oncology 1/2012

Open Access 01-12-2012 | Research

Decreased expression of survivin, estrogen and progesterone receptors in endometrial tissues after radiofrequency treatment of dysfunctional uterine bleeding

Authors: Geping Yin, Tongyu Zhu, Juan Li, Ming Chen, Shujun Yang, Xiaoli Zhao

Published in: World Journal of Surgical Oncology | Issue 1/2012

Login to get access

Abstract

Background

The purpose of the research is to study the histopathology and expression of survivin, estrogen and progesterone receptors (ER/PR) in the endometrium of patients with dysfunctional uterine bleeding (DUB) treated with radiofrequency endometrial ablation (REA).

Methods

A total of 98 DUB patients were enrolled in this case–control study. Among them, 66 underwent REA treatment and 32 optioned for hormone therapy as the control group. Immunohistochemical analysis for survivin, ER and PR expression was carried out on endometrial tissue samples collected before and 6 to 7 months after treatment for both groups.

Results

Both hormone and REA treatment ameliorated menstrual bleeding of DUB patients, with the latter showing a significantly higher effective rate. Endometrial surface tissue was replaced by fibrosis tissue in the REA treatment group. REA treatment also significantly reduced the expression of survivin, ER, and PR. Endometrial surface tissues collected from the hormone-treated control group neither showed any apparent morphological alteration nor in the expression of those receptors.

Conclusions

REA treatment changed endometrial surface tissue type from gland rich to gland poor, and significantly decreased the expression of survivin, ER, and PR. This may be an important contributing mechanism for the long-term curative effect and prevention of DUB recurrence.
Appendix
Available only for authorised users
Literature
2.
go back to reference Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A: Treatment of menorrhagia. Am Fam Physician. 2007, 75: 1813-1819.PubMed Apgar BS, Kaufman AH, George-Nwogu U, Kittendorf A: Treatment of menorrhagia. Am Fam Physician. 2007, 75: 1813-1819.PubMed
3.
go back to reference Hodgson DA, Feldberg IB, Sharp N, Cronin N, Evans M, Hirschowitz L: Microwave endometrial ablation: development, clinical trials and outcomes at three years. Br J Obstet Gynecol. 1999, 106: 684-694. 10.1111/j.1471-0528.1999.tb08368.x.CrossRef Hodgson DA, Feldberg IB, Sharp N, Cronin N, Evans M, Hirschowitz L: Microwave endometrial ablation: development, clinical trials and outcomes at three years. Br J Obstet Gynecol. 1999, 106: 684-694. 10.1111/j.1471-0528.1999.tb08368.x.CrossRef
4.
go back to reference Li D: The curative effect of RU486 for the treatment of dysfunctional uterine bleeding (in Chinese - English abstract available). Chin J Mod Drug Appl. 2009, 3: 104-105. Li D: The curative effect of RU486 for the treatment of dysfunctional uterine bleeding (in Chinese - English abstract available). Chin J Mod Drug Appl. 2009, 3: 104-105.
5.
go back to reference Xiu-min F: Clinical analysis of mifepristone treatment of 68 cases of perimenopausal dysfunctional uterine bleeding (in Chinese - English abstract available). Medical Information. 2010, 23: 905-906. Xiu-min F: Clinical analysis of mifepristone treatment of 68 cases of perimenopausal dysfunctional uterine bleeding (in Chinese - English abstract available). Medical Information. 2010, 23: 905-906.
6.
go back to reference Zarek S, Sharp HT: Global endometrial ablation devices. Clin Obstet Gynecol. 2008, 51: 167-175. 10.1097/GRF.0b013e3181621f97.CrossRefPubMed Zarek S, Sharp HT: Global endometrial ablation devices. Clin Obstet Gynecol. 2008, 51: 167-175. 10.1097/GRF.0b013e3181621f97.CrossRefPubMed
7.
go back to reference Taskin O, Onoglu A, Inal M, Turan E, Sadik S, Vardar E, Postaci H, Wheeler JM: Long-term histopathologic and morphologic changes after thermal endometrial ablation. J Am Assoc Gynecol Laparosc. 2002, 9: 186-190. 10.1016/S1074-3804(05)60130-2.CrossRefPubMed Taskin O, Onoglu A, Inal M, Turan E, Sadik S, Vardar E, Postaci H, Wheeler JM: Long-term histopathologic and morphologic changes after thermal endometrial ablation. J Am Assoc Gynecol Laparosc. 2002, 9: 186-190. 10.1016/S1074-3804(05)60130-2.CrossRefPubMed
8.
go back to reference Thijssen RF: Radiofrequency induced endometrial ablation: an update. Br J Obstet Gynaecol. 1997, 104: 608-613. 10.1111/j.1471-0528.1997.tb11541.x.CrossRefPubMed Thijssen RF: Radiofrequency induced endometrial ablation: an update. Br J Obstet Gynaecol. 1997, 104: 608-613. 10.1111/j.1471-0528.1997.tb11541.x.CrossRefPubMed
9.
go back to reference Dequesne JH, Gallinat A, Garza-Leal JG, Sutton CJ, van der Pas HF, Wamsteker K, Chandler JG: Thermoregulated radiofrequency endometrial ablation. Int J Fertil Womens Med. 1997, 42: 311-318.PubMed Dequesne JH, Gallinat A, Garza-Leal JG, Sutton CJ, van der Pas HF, Wamsteker K, Chandler JG: Thermoregulated radiofrequency endometrial ablation. Int J Fertil Womens Med. 1997, 42: 311-318.PubMed
10.
go back to reference Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK: Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol. 2011, 117: 109-118. 10.1097/AOG.0b013e3182020401.CrossRefPubMed Clark TJ, Samuel N, Malick S, Middleton LJ, Daniels J, Gupta JK: Bipolar radiofrequency compared with thermal balloon endometrial ablation in the office: a randomized controlled trial. Obstet Gynecol. 2011, 117: 109-118. 10.1097/AOG.0b013e3182020401.CrossRefPubMed
11.
go back to reference El-Nashar SA, Hopkins MR, Creedon DJ, Cliby WA, Famuyide AO: Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: A population-based cohort. J Minim Invasive Gynecol. 2009, 16: 692-699. 10.1016/j.jmig.2009.06.022.PubMedCentralCrossRefPubMed El-Nashar SA, Hopkins MR, Creedon DJ, Cliby WA, Famuyide AO: Efficacy of bipolar radiofrequency endometrial ablation vs thermal balloon ablation for management of menorrhagia: A population-based cohort. J Minim Invasive Gynecol. 2009, 16: 692-699. 10.1016/j.jmig.2009.06.022.PubMedCentralCrossRefPubMed
12.
go back to reference Yin GP, Chen M, Shao X, Zhu TY, Wang YZ: Radiofrequency minimally invasive treatment of uterine benign diseases (in Chinese - English abstract available). Progress Obstetrics and Gynecology. 2003, 12: 200-203. Yin GP, Chen M, Shao X, Zhu TY, Wang YZ: Radiofrequency minimally invasive treatment of uterine benign diseases (in Chinese - English abstract available). Progress Obstetrics and Gynecology. 2003, 12: 200-203.
13.
go back to reference Higham JM, O’Brien PM, Shaw RW: Assessment of menstrual blood loss using a pictorial chart. BJOG. 1990, 97: 734-739. 10.1111/j.1471-0528.1990.tb16249.x.CrossRef Higham JM, O’Brien PM, Shaw RW: Assessment of menstrual blood loss using a pictorial chart. BJOG. 1990, 97: 734-739. 10.1111/j.1471-0528.1990.tb16249.x.CrossRef
14.
go back to reference Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I: Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002, 184: 105-116. 10.1016/S0304-3835(02)00190-8.CrossRefPubMed Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I: Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett. 2002, 184: 105-116. 10.1016/S0304-3835(02)00190-8.CrossRefPubMed
15.
go back to reference Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, Jin H, Gu C, Zheng W: Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Modern Pathology. 2009, 22: 699-708. 10.1038/modpathol.2009.25.CrossRefPubMed Chen X, Zhang Z, Feng Y, Fadare O, Wang J, Ai Z, Jin H, Gu C, Zheng W: Aberrant survivin expression in endometrial hyperplasia: another mechanism of progestin resistance. Modern Pathology. 2009, 22: 699-708. 10.1038/modpathol.2009.25.CrossRefPubMed
16.
go back to reference Hu K, Zhong G, He F: Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer. 2005, 15: 537-541. 10.1111/j.1525-1438.2005.15321.x.CrossRefPubMed Hu K, Zhong G, He F: Expression of estrogen receptors ERalpha and ERbeta in endometrial hyperplasia and adenocarcinoma. Int J Gynecol Cancer. 2005, 15: 537-541. 10.1111/j.1525-1438.2005.15321.x.CrossRefPubMed
17.
go back to reference Kalogiannidis I, Bobos M, Papanikolaou A, Makedos A, Amplianitis I, Vergote I, Nenopoulou E, Makedos G: Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol. 2008, 29: 19-25.PubMed Kalogiannidis I, Bobos M, Papanikolaou A, Makedos A, Amplianitis I, Vergote I, Nenopoulou E, Makedos G: Immunohistochemical bcl-2 expression, p53 overexpression, PR and ER status in endometrial carcinoma and survival outcomes. Eur J Gynaecol Oncol. 2008, 29: 19-25.PubMed
Metadata
Title
Decreased expression of survivin, estrogen and progesterone receptors in endometrial tissues after radiofrequency treatment of dysfunctional uterine bleeding
Authors
Geping Yin
Tongyu Zhu
Juan Li
Ming Chen
Shujun Yang
Xiaoli Zhao
Publication date
01-12-2012
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2012
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-10-100

Other articles of this Issue 1/2012

World Journal of Surgical Oncology 1/2012 Go to the issue